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Abstract
We previously developed a panel of neutralizing monoclonal antibodies against Dengue virus (DENV)-1, of which few
exhibited inhibitory activity against all DENV-1 genotypes. This finding is consistent with reports observing variable
neutralization of different DENV strains and genotypes using serum from individuals that experienced natural infection or
immunization. Herein, we describe the crystal structures of DENV1-E111 bound to a novel CC9 loop epitope on domain III
(DIII) of the E protein from two different DENV-1 genotypes. Docking of our structure onto the available cryo-electron
microscopy models of DENV virions revealed that the DENV1-E111 epitope was inaccessible, suggesting that this antibody
recognizes an uncharacterized virus conformation. While the affinity of binding between DENV1-E111 and DIII varied by
genotype, we observed limited correlation with inhibitory activity. Instead, our results support the conclusion that potent
neutralization depends on genotype-dependent exposure of the CC9 loop epitope. These findings establish new structural
complexity of the DENV virion, which may be relevant for the choice of DENV strain for induction or analysis of neutralizing
antibodies in the context of vaccine development.
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Introduction
Dengue viruses (DENV) are mosquito-borne viruses of the
Flavivirus genus, which include other significant human patho-
gens such as West Nile (WNV), Japanese encephalitis, and yellow
fever viruses. Infection with DENV can cause symptoms in
humans ranging from a mild febrile illness (Dengue Fever, DF) to
a more severe hemorrhagic fever (DHF) and life-threatening
dengue shock syndrome (DSS). Currently, it is estimated that
DENV infects ,50 to 100 million people per year resulting in
,250,000 to 500,000 cases of DHF/DSS [1]. The four serotypes
of DENV (DENV-1, DENV-2, DENV-3, and DENV-4)
comprise a genetically related yet antigenically distinct serocom-
plex, varying from one another by 25 to 40% at the amino acid
level. Each DENV serotype is further divided into genotypes,
which can vary up to 3% [2,3]. Currently, there are no specific
antiviral therapies or vaccines approved for use in humans, and
treatment of severe disease remains supportive in a tertiary care
setting.
The humoral response contributes to protection and also,
paradoxically to the pathogenesis of severe DENV disease.
Infection with a given serotype is believed to induce durable
levels of neutralizing antibodies that provide life-long immunity
against subsequent challenge by a strain of the same serotype [4].
However, secondary infection with a heterologous serotype
increases the relative risk of developing DHF and DSS [5]. A
favored hypothesis is that during secondary infection poorly
neutralizing cross-reactive antibodies from the primary infection
enhance infection of the heterologous virus in cells bearing Fc-c
receptors [6]. Recent studies in non-human primates and mice
have confirmed that passive transfer of anti-DENV monoclonal or
polyclonal antibodies can augment replication of a heterologous
DENV in challenge models, and in some cases cause a lethal
vascular leakage syndrome that resembles DSS [7–9].
Humoral protection against DENV correlates with the induc-
tion of a neutralizing antibody response against the envelope (E)
protein on the surface of the virion ([10] and reviewed in [11]).
The ectodomain of the DENV E protein is composed of three
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domains [12]: DI is a central nine-stranded b-barrel domain, DII
consists of two finger-like protrusions from DI and contains the
hydrophobic peptide required for virus fusion, and DIII is an
immunoglobulin-like domain on the other side of DI that has been
proposed to interact with as yet uncharacterized host receptor(s).
Neutralizing monoclonal antibodies (MAbs) against the different
DENV serotypes map to all three domains [13–19], although
many potently inhibitory mouse MAbs localize to DIII [13]. To
date, three epitopes have been established on DIII [7,20,21]:
MAbs binding the lateral ridge or A-strand epitope are relatively
inhibitory, whereas MAbs recognizing the AB loop neutralize
infection less efficiently or not at all [22], presumably due to poor
epitope accessibility on the virion.
Cryo-electron microscopy (cryo-EM) studies have revealed that
the E proteins of mature flavivirus virions form anti-parallel dimers
that lie flat against the surface of the virion and are arranged with
T = 3 quasi-icosahedral symmetry [23,24]. In this configuration, E
proteins exist in three distinct chemical environments defined by
their proximity to the 2-, 3-, or 5-fold axis of symmetry [23,24].
While 180 copies of the E protein are present on all flavivirus
virions, the different environments imposed by the quasi-icosahe-
dral symmetry make some epitopes unequally accessible. Epitope
exposure also may be affected by neighboring E proteins in
adjacent symmetry units, or by the presence or absence of prM in
the case of immature, partially mature, and mature virions [25–
30]. The arrangement of the E proteins on the surface of the virion
can be modulated over time and across a range of temperatures
due to the intrinsic conformational heterogeneity of virions [31,32]
Consequently, the accessibility of epitopes can vary across
structurally distinct epitopes, ultimately affecting the number of
sites available for antibody binding and neutralization.
Recently, we generated a panel of 79 MAbs against DENV-1 to
define how antibodies neutralized different DENV-1 genotypes
[17]. Within this panel, 15 MAbs were potently neutralizing, and
most mapped to previously identified epitopes in DIII, although
few retained strong inhibitory activity against heterologous
DENV-1 genotypes. Prior studies have described disparate
neutralization of DENV strains corresponding to different
genotypes within a serotype with serum from natural infection
[33–35] or after immunization with live-attenuated tetravalent
vaccine candidates [34,36–38]. One such DIII-specific neutraliz-
ing MAb from our panel, DENV1-E111 (henceforth termed E111)
potently neutralized infection of a genotype 2 DENV-1 (strain
16007, EC50 of ,4 ng/ml), but inhibited infection of a genotype
4 virus poorly (strain Western Pacific-74 (West Pac-74), EC50 of
,15,200 ng/ml). Sequence analysis of the variation between
residues 296–400 of DIII for 16007 or West Pac-74 revealed only
two differences (amino acids 339 and 345), with amino acid 345 as
the only residue that varied in all five DENV-1 genotypes.
Here, we determined the crystal structures of an E111 single-
chain variable fragment (scFv) in complex with DIII of 16007 and
the E111 Fab in complex with DIII from West Pac-74. E111
bound to a previously uncharacterized epitope centered on the
CC9 loop of DIII, which should not be exposed on the virion
according to existing flavivirus atomic models; our structural data
defining the CC9 loop epitope of E111 was supported by extensive
mutagenesis and binding analyses. While E111 showed a higher
affinity and longer half-life of binding to DIII of 16007 (genotype
2) compared to DIII from several other DENV-1 genotypes, this
did not explain the disparity in neutralization potency for viruses
from all five genotypes. Mutation at position 345 of West Pac-74
DIII to the corresponding residue in 16007 resulted in increased
E111 binding, but only a small improvement in neutralization
potency, suggesting that differences in amino acids within the
epitope among genotypes could not account for the phenotype.
However, neutralization of DENV-1 West Pac-74 with E111 was
enhanced by incubating virus-antibody complexes at higher
temperature or for longer times, whereas this treatment failed to
equivalently impact inhibition of strain 16007 by E111. Our
experiments suggest that the conformational ensemble of DENV
virion structures differs in a genotype-dependent manner, which
impacts the neutralizing activity of antibodies that recognize
nominally cryptic epitopes.
Results
Structure of E111 in complex with DIII
We initially formed complexes of E111 Fab with soluble,
bacterially expressed DIII (residues 293–399) cloned from 16007
and West Pac-74 DENV-1 strains (Figure S1, and data not
shown). Several conditions yielded diffracting crystals of the 16007
DIII-E111 Fab complex but failed to diffract better than ,6.0 A˚
resolution. As an alternative strategy, we cloned the heavy (VH)
and light chain (VL) variable domain sequences from the E111
hybridoma to create an scFv. Two constructs of the E111 scFv
were generated, with either the VL or VH sequence at the N-
terminus, separated with a (GGGGS)3 linker, and a C-terminal
hexahistadine tag for affinity purification. These inserts were
cloned into the pAK400 vector that contains a pelB leader
sequence for targeting the polyprotein transcript to the oxidative
environment of the bacterial periplasm [39]. Sequential purifica-
tion by nickel affinity and size exclusion chromatography revealed
two species of scFv: a non-disulfide domain-swapped dimer and a
monomer. For our structural analysis, we used the monomeric
species with VL at the N-terminus (Figure S1A).
We determined the structure of E111 scFv in complex with DIII
of DENV-1 16007 to 2.5 A˚ resolution (model statistics are in
Table 1). There were no major structural perturbations to the
immunoglobulin-like b-sandwich topology of DIII found in other
flavivirus E proteins, with a root mean squared displacement of
0.7 A˚ compared to unbound DIII. The E111 scFv adopted the
predicted variable domain assembly (Figure 1A). The binding
Author Summary
Within each Dengue virus (DENV) serotype, viruses are
subdivided into genotypes based upon the protein
sequence variation. Infection with a given serotype is
believed to induce neutralizing antibodies that provide
long-term immunity against secondary infection by a
strain of the same serotype. However, recent studies
suggest that some classes of neutralizing antibodies fail to
inhibit infection equivalently for all genotypes within a
DENV serotype. DENV1-E111 is an example of an antibody
that differentially neutralizes infection of DENV-1 strains.
We used structural and molecular approaches to deter-
mine that DENV1-E111 binds to an epitope in domain III of
the envelope protein. Although the epitope sequence
varied between DENV-1 genotypes, inhibitory activity of
the antibody remained unequal when we exchanged the
amino acids within the epitope among genotypes.
Docking of our structures onto DENV virion models
revealed that the DENV1-E111 epitope was inaccessible,
suggesting that the antibody recognizes an uncharacter-
ized virus conformation. Our studies suggest that DENV
virion structures differ in a genotype-dependent manner,
which can impact the inhibitory activity of antibodies that
recognize cryptic epitopes.
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interface had an average degree of shape complementarity
(Sc = 0.68, with Sc = 1.0 a perfect score) for antibody-antigen
interactions and 2,095 A˚2 of combined surface area. The light and
heavy chains engaged DIII equivalently, with a combined buried
surface area of 1,017 A˚2 (460 A˚2 of DIII and 557 A˚2 of the light
chain) versus 1,078 A˚2 (550 A˚2 of DIII and 528 A˚2 of the heavy
chain) (Figure 1C). The interaction between E111 and DIII of
strain 16007 was dominated by hydrophobic interactions, in
addition to six direct hydrogen bonds and fourteen water-
mediated networks at the interface of the complex (Table S1).
We obtained crystals of DIII of West Pac-74 in complex with
E111 Fab that diffracted to 3.8 A˚ resolution (Figure S1B). There
were two complexes in the asymmetric unit, and non-crystallo-
graphic symmetry restraints were applied in the refinement (model
statistics are in Table 1). The two Fabs have essentially identical
structures with the notable exception of the elbow angles between
the variable and constant domains ((149.0u versus 133.5u as
calculated by the RBOW server [40]). As with the co-crystal
structure with the E111 scFv and DIII of 16007, there were limited
conformational changes in the West Pac-74 DIII upon E111 Fab
ligation (R.m.s.d = 0.8 A˚). The E111 Fab-DIII interface also had a
similar average degree of shape complementarity (Sc = 0.65) and
total buried surface area (2,076.5 A˚2). Overall, the E111 scFv and
Fab structures (DIII and Fv domains) varied little from one
another in terms of structure (R.m.s.d = 0.3 A˚) or orientation of
engagement of DIII (Figure S1C).
E111 engaged discontinuous segments of DIII of 16007 and
West Pac-74 including the N-terminal linker (residues 300–301),
C-strand, CC9 loop, C9-strand (residues 334–351), EF loop (372),
and FG loop (residues 382–384) (Figure 1D); together, these form
a single convex surface patch of 25 residues. A total of 20 residues
of E111 contacted DIII: 8 from the light chain and 12 from the
heavy chain. The heavy and light chains both formed contacts
with three of the same amino acid residues (S338, G344, and
A345). The E111 binding site was centered on the CC9 loop (7 of
25 residues), a previously uncharacterized epitope for flavivirus
neutralizing MAbs (Figure 1E). Analysis of the CC9 loop
sequences from other DENV serotypes revealed significant
variation (Figure 1F), which likely explains the type-specificity
(i.e., does not bind or neutralize other DENV serotypes) of E111
[17].
We previously observed reduced binding of E111 to DENV-1
West Pac-74 strain (genotype 4) in a virus capture ELISA, which
correlated with a ,4,100-fold decrease in neutralization efficiency
[17]. E111 contacted every residue in the CC9 loop of 16007 DIII,
as well as residues on the adjacent C- and C9-strands. Sequence
variation between 16007 (genotype 2) and West Pac-74 (genotype
4) occurs at two DIII positions, 339 and 345, both of which are
directly contacted by E111.
Binding of mutant DIII to E111
As variation within the CC9 loop and surrounding regions
might affect the differential binding and neutralization of E111 for
different DENV-1 genotypes, we generated a library of soluble
DENV-1 DIII proteins based upon natural sequence variation of
Table 1. Data collection and refinement statistics.
Data collection
16007 DIII Western Pacific-74 DIII
E111 scFv E111 Fab
Space group P43212 P21
Cell dimensions (A˚) a = b = 135.2, c = 52.2 a = 82.9, b = 52.0, c = 136.4
Total reflections 105832 44787
Unique reflections 17132 11029
Resolution 50.0-2.5 A˚ (2.59-2.50) 50.0-3.8 A˚ (3.97-3.8)
Completeness 98.1% (94.3%) 97.4% (98.6%)
Rsym 9.2% (49.4%) 12.0% (51.4%)
I/s (I) 18.78 (2.35) 9.74 (1.91)
Refinement
Resolution 41.36-2.50 A˚ (2.65-2.50) 43.45-3.79 A˚ (4.18-3.80)
R-work 17.2% 23. 7%
R-free 22.9% 27.8%
Ramachandran favored 97.4% 97.0%
Ramachandran outliers 0.3% 0.4%
Rotamer outliers 0% 0.0%
Protein residues 328 1060
Water molecules 139 Not Placed
R.m.s.d. bond angles 0.004u 0.003u
R.m.s.d. bond lengths 0.883 A˚ 0.860 A˚
MolProbity score 100th percentile 100th percentile
MolProbity clash score 99th percentile 97th percentile
Values in parentheses are for the highest resolution shell.
doi:10.1371/journal.ppat.1002930.t001
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all five DENV-1 genotypes and tested their binding kinetics at
25uC to E111 by surface plasmon resonance (SPR) (Figure 2A,
2F, and Table 2). Whereas E111 had a KD of 18.060.08 nM
and a half-life of 194 seconds for DIII from 16007, its interaction
with West Pac-74 DIII was weaker with a KD of 415624 nM and
half-life of 6.5 seconds (Figure 2B and 2C). Mutagenesis of a
Figure 1. E111 in complex with DENV-1 DIII. A ribbon diagram of the crystal structure of (A) E111 scFv in complex with DENV-1 strain 16007 DIII
and (B) E111 Fab in complex with DENV-1 strain West Pac-74 DIII. The light chain is colored in cyan and the heavy chain in magenta. 16007 DIII is
colored in light gray and West Pac-74 DIII is in gray. (C) A surface model showing the contact residues in the scFv complex. Contacts in the scFv are
highlighted by light chain (cyan) or heavy chain (magenta) contacts. DIII contacts are highlighted by heavy chain (magenta), light chain (cyan), or
both chains (green). (D) A ribbon diagram showing the residues of DIII contacted by the E111 scFv in the crystal structure. DIII residues that are
contacted by the heavy and light chains of E111 (338, 344, and 345) are labeled. (E) A close-up of the contacts made by E111 in the CC9 loop of 16007
DIII (yellow) or West Pac-74 DIII (white). (F) Sequence of the four segments of 16007 DIII contacted by E111 aligned with the analogous residues of
the other four DENV-1 genotypes and three serotypes. Residues are colored as in Figure 1D.
doi:10.1371/journal.ppat.1002930.g001
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TRS at position 339 had a similar affinity as wild type 16007 DIII
(KD of 16.660.17 nM; t1/2 = 222.4 seconds (Figure 2D)). The
crystal structures show that the additional methyl group present in
the 16007 Thr residue does not contact E111, whereas the Ser/
Thr hydroxyl groups both make equivalent hydrogen bonds with
TyrL30B in CDR1 of the E111 light chain (see Figure 1E). In
contrast, an ARV change at position 345 of 16007 DIII (to the
residue in West Pac-74) decreased the affinity of binding such that
kinetics became comparable to West Pac-74 DIII with a KD of
1143660 nM and half-life of 5.3 seconds (Figure 2E). The side
chain of Ala 345 of 16007 makes limited contact with E111, and
the additional two methyl groups in Val 345 of West Pac-74 appear
to be tolerated sterically at the E111 interface with only minor
structural perturbations. However, position 345 and the adjacent
CC9 loop residues participate in an extensive network of hydrogen
bonds with E111 (Figure S1D), and we speculate that Val 345
leads to a dramatically faster off-rate by subtle destabilization of this
interface. Due to the low resolution of the E111 Fab-West Pac-74
DIII structure, ordered water molecules could not be modeled,
making precise comparison of the interfaces difficult.
While the on-rates for E111-DIII interactions were relatively
constant, the off-rate governed the differences in affinity for the
Figure 2. Kinetic analysis of E111 interaction with DENV genotypes and single variants. (A) Ribbon diagram of DENV-1 16007 DIII with
amino acids highlighted corresponding to tested mutants. Lateral ridge mutants and A-strand mutants are shown in gray. Amino acids representing
genotypic variation of DENV-1 are shown in green. B–E. SPR traces are presented of E111 MAb interacting with (B) 16007 DIII, (C) West Pac-74 DIII, (D)
16007 DIII containing a T339S substitution or (E) 16007 DIII containing an A345V substitution. A single representative sensogram is shown for each
DIII variant. The experimental curves (gray lines) were fit using a 1:1 Langmuir analysis (black lines), after double referencing, to determine the kinetic
parameters presented in panel F and Table 2. Graphical representation of E111 binding to 16007 DIII mutants is presented according to the half-life
(in seconds) of the interaction. The results are representative of a minimum of three independent experiments, with error bars showing standard
deviation. Statistical significance was determined using a paired student t-test comparing the half-life of the E111 binding to 16007 DIII to that of
another DIII variant.
doi:10.1371/journal.ppat.1002930.g002
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DIII variants (Figure 2F). DIII from strain 3146 SL varies in six
positions from 16007, including a valine at position 345. Kinetic
analysis with 3146 SL DIII revealed a decreased half-life
(5.5 seconds) as compared to 16007. Substitution of individual
amino acids corresponding to variation in strain 3146L (D341N
(CC9 loop) or A369T (E-strand)) had little negative effect on the
half-life of strain 16007 (t1/2 of 173 seconds and 182 seconds,
respectively). One amino acid difference (V380I (F-strand)) in 3146
SL caused a small increase in the half-life (t1/2 of 296 seconds)
when inserted into DIII of 16007, despite its side chain location
,10 A˚ from DIII. An ARI change at position 345 was the only
difference in DIII sequence between strains 16007 (genotype 2)
and TVP-5175 (genotype 3); this single amino acid substitution
reduced the half-life (t1/2 of 2.2 seconds) and affinity of binding
(KD of 19816441 nM). Precise kinetic measurements with DIII
from TVP-2130 (genotype 1) were limited by non-specific
interactions, and thus not analyzed (data not shown). However,
a DIII variant of 16007 that included the unique variation of strain
TVP-2130 in the CC9 loop (L351V) showed a decreased half-life
with E111 (t1/2 of 32.9 seconds) likely due to the disruption of
optimal hydrophobic contact with Tyr30B of the variable light
chain CDR1 loop. As a control, insertion of a triple mutation of
K310E/T329E/K361T into the 16007 DIII lateral ridge and A-
strand epitopes did not alter significantly E111 binding affinity or
half-life (t1/2 of 155 seconds). SPR binding studies with the E111
scFv showed a similarly reduced half-life for West Pac-74 DIII
compared to 16007 DIII (Table 2). A similar kinetic pattern of
E111-DIII interactions also was observed at 37uC (data not
shown). Overall, our genetic and biophysical studies support the
crystallographic analysis and establish the CC9 loop as important
for recognition of DIII by E111.
Differential neutralization of DENV-1 genotypes by E111
We determined the inhibitory activity of E111 against strains
representing the three other genotypes of DENV-1: TVP-2130
(genotype 1), TVP-5175 (genotype 3), and 3146 SL (genotype 5).
Only strains corresponding to genotypes 2 and 5 (16007 and 3146
SL) were neutralized potently by E111 with EC50 values of
3.862.0 ng/ml and 22610 ng/ml, respectively (Figure 3A and
Table 3). In comparison, E111 neutralized strains of genotype 1,
3, and 4 poorly with EC50 values ranging from 9,70063,200 ng/
ml to greater than 25,000 ng/ml. Although rather extreme
differences in E111-mediated neutralization were observed with
different genotypes, this pattern failed to correlate with the KD or
half-life of binding with recombinant DIII by SPR (see Table 2).
These results suggest that DIII epitope sequence-independent
factors (e.g., CC9 epitope accessibility on the virion or secondary
binding sites in other domains) likely contribute to the differential
genotype neutralization by E111.
Substitution of V345A into the West Pac-74 strain only
modestly enhances neutralizing activity of E111
Our SPR data demonstrated that substitution of a single
residue (ARV) at position 345 of soluble 16007 DIII reduced the
E111 binding half-life to that observed with DIII of West Pac-74.
To test the effect of a reciprocal VRA change at position 345 in
the West Pac-74 strain, we used a reverse genetic system:
DENV-1 West Pac-74 reporter virus particles (RVP) [32,41]
incorporating a single V345A mutation were analyzed for
sensitivity to MAb neutralization. Whereas DENV1-E103
MAb (which maps to residues T303, G328, T329, D330, and
P332 on the lateral ridge of DIII [17]) neutralized both wild-type
and V345A DENV-1 West Pac-74 RVP equivalently
(Figure 3B), E111 showed only moderately enhanced neutral-
ization of the V345A-containing RVP (3.6-fold, P,0.05,
Figure 3C). Although the V345A change improved neutraliza-
tion of West Pac-74 by E111, it failed to restore the sensitivity
seen with DENV-16007 RVP or the fully infectious virus. Thus,
either additional amino acid residues accounted for the
genotypic difference in neutralization or the epitope was not
displayed equivalently on the two viruses.
Table 2. SPR results for binding of DENV-1 E111 to DIII variants.
DIII variant Binding parameters for DENV1-E111
a
ka (105M-1s-1) kd (1023s-1) KD (nM) x2 t1/2 (sec) t K significance
b
16007 1.9860.09 3.5660.03 1860.08 1.460.6 194.161.5 -
Western Pacific-74 2.5660.18 106.462 416624 2.461.1 6.560.1 ***
3146 SL 2.6761.02 141.6664 523632 3.660.8 5.562.0 ***
TVP-5175 1.6260.28 312.3613.6 19816441 0.260.08 2.260.1 ***
16007 K310E/T329E/K361T 1.2160.4 4.5760.77 39.860.9 0.2960.2 154.9629 N.S.
16007 T339S 1.9160.4 3.1360.27 16.660.17 0.7560.6 222.4619 N.S.
16007 D341N 2.1360.2 4.0260.3 18.960.06 0.6360.08 173.1614 N.S.
16007 A345V 1.1460.003 131.068.8 1143660 3.361.8 5.360.4 ***
16007 L351V 2.1160.7 23.760.8 107.260.01 0.2360.1 32.9611 **
16007 A369T 1.5160.12 3.8360.5 25.360.1 0.5360.3 182.3625 N.S.
16007 V380I 1.2460.05 2.3660.3 19.060.2 0.4560.5 296.4634 *
E111 scFv-16007 DIII 2.8860.7 6.9560.7 24.663.5 0.21760.09 100.569.7 **
E111 scFv- West Pac-74 DIII 1.5160.08 275621.9 18306169 0.3160.08 2.5360.2 ***
aValues for ka, kd, KD are means 6 standard deviations. KD = kd/ka; t1/2 = ln(2)/kd.
bP-values were determined in comparison to the 16007 half-life value by t-test:
*P,0.05,
**P,0.01,
***P,0.001.
doi:10.1371/journal.ppat.1002930.t002
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The structural basis of E111 neutralization
Because of the differential neutralization of West Pac-74 and
16007 by E111, we evaluated its epitope in the context of full-
length E protein structures. We docked our scFv–DIII complex
onto the available structure of the pre-fusion DENV E protein
dimer (PDB ID 1OAN [12]), and compared this to other
characterized DIII-specific anti-flavivirus neutralizing MAbs
(Figure 4A). E111 engaged the face of DIII opposite to the one
seen previously with 1A1D-2 and 4E11 (A-strand) [31,42] or
WNV-E16 (lateral ridge) [25]. The E111 Fab was rotated in a
downward orientation compared to the WNV E16 Fab
(Figure 4A) or the A-strand DENV Fabs docked onto the same
structure (data not shown). Based on this docking it appears that
E111 does not bind the outer exposed surface of the DENV-1 E
protein but rather a determinant that is localized to the interior of
the virus.
Antibody neutralization of flaviviruses can occur by blocking
attachment, internalization, and/or endosomal fusion. Prior to
viral fusion, the E proteins on the surface of the virus dissociate
from their dimeric hairpin arrangement to form trimeric spikes
upon acidification in the late endosome. This rearrangement is
essential to allow the newly exposed fusion loop to insert into the
endosomal membrane. While the exact structural transitions of the
E proteins from dimer to trimer remain unknown, DIII is
displaced ,70u from the pre-fusion structure and settles adjacent
to DI in the post-fusion state [43–45]. We examined structurally
how E111 could disrupt a post-attachment step by docking our
Fab-DIII complex onto the structure of the DENV-1 post-fusion
trimer [45]. While the Fab does not clash with the adjacent E
protein in the DENV-2 pre-fusion dimer structure (Figure 4A),
the light chain of E111 sterically would inhibit formation of the
post-fusion trimer (Figure 4B) by clashing with the neighboring
DI of an adjacent E protein. Thus, from a structural perspective,
E111 likely hinders the necessary conformational change from E
protein homodimer to homotrimer, and limits viral fusion and
infection.
To begin to understand the mechanism of E111-mediated
neutralization, we performed pre- and post-attachment neutrali-
zation assays [10,18,25,46]. E111 MAb was incubated with
DENV-1 16007 before or after virus binding to BHK21-15 cells,
and infection was measured by the plaque reduction assay. E111
efficiently neutralized DENV-1 when premixed with the virus
before cell attachment or when added after the virus had attached
to the cell surface (Figure 4C). This result suggests that E111 has
the capacity to neutralize infection after virus attachment has
occurred, and is consistent with previously observed patterns of
inhibition seen for potently neutralizing DIII-specific antibodies
[18,25,46,47].
The E111 epitope is not accessible in the cryo-electron
microscopy models of DENV
We next docked our E111-DIII structures onto the cryo-EM-
derived model of the mature DENV virion [23]. With three
envelope glycoproteins in the asymmetric unit, there are three
potential E111-binding environments. However, in the mature
DENV model, the E111 epitope was not accessible on the surface
in any of the three symmetry environments (Figure 5A). Instead,
the E111 epitope was buried in E protein contacts on the virion
surface (Figure S2A–E).
Because some anti-flavivirus MAbs (e.g., DII fusion loop-
specific) show differential neutralization of mature and partially
mature virions, we hypothesized that intrinsic differences in
particle maturation among different DENV-1 genotypes might
impact neutralization by E111. However, the distinct neutraliza-
tion profiles by E111 of DENV-1 16007 and West Pac-74 were not
explained by differential epitope accessibility due to variation in
the maturation state of the viruses (Figure S3). As in the mature
virion model, the E111 epitope also appeared inaccessible on the
cryo-EM model of the immature DENV virion [48], due to the
trimeric arrangement of prM-E, which positions the epitope
farther into the virus interior (Figure 5B and Figure S2 F–H).
The cryo-EM model of DENV-2 in complex with the 1A1D-2
Fab describes one conformational ensemble that is a consequence
of ‘‘breathing’’ of a virus particle [31]. The 1A1D-2 epitope is
partially inaccessible in the unbound conformation of the mature
virion, and an increase in temperature allows for dissociation of E
protein homodimers and greater exposure of the A-strand of DIII,
a major component of the 1A1D-2 epitope. Although there are
major rearrangements of the E proteins in this structure, E111
binding still would be prohibited by steric clashes of adjacent E
protein monomers (Figure 5C and Figure S2 I–K) at the 3- and
5-fold axes of symmetry. While access of the 2-fold axis is not
hindered by contacts with neighboring E proteins, its orientation
would inhibit an immunoglobulin from binding this site. Based on
these models, it appears unlikely that E111 binds to DENV-1 in
the conformations that have been described by cryo-EM to date.
Neutralization of DENV-1 by E111 varies with time and
temperature in a genotype-dependent manner
Changes in time and temperature of binding can expose
otherwise cryptic epitopes and enhance neutralizing activity of
some MAbs [31,32,49]. Given our structural, biophysical, genetic,
and virological data, we hypothesized that the CC9 epitope on
West Pac-74 (genotype 4) was less well exposed compared to
16007 (genotype 2). Alternatively, a difference in the range of the
ensemble structures sampled by the two viruses could contribute to
the differential neutralization by E111. We compared the time-
and temperature-dependence of neutralization of E111 with
16007 and observed little change in EC50 values after incubation
of 16007 in the presence of antibody at 37uC or 40uC from 1 to 7
or 4.5 hours, respectively (Figure 6A and E); this suggests that
the CC9 loop epitope generally is accessible among the ensemble
of conformations sampled by 16007 under steady-state conditions.
Similarly, a modest change in the pattern of neutralization was
observed with E111 and West Pac-74 RVP after incubation at
37uC up through 7 hours (Figure 6B). However, we observed a
marked increase in neutralization when E111 and West Pac-74
RVP were incubated at 40uC for 4.5 hours, with a 20-fold
(P,0.001) reduction in the EC50 value (Figure 6F). By
comparison, 16007 exhibited only a 3.5-fold fold increase in
potency over the same interval. A shift in EC50 was observed with
Figure 3. E111 neutralization of different DENV-1 genotypes is only partially dependent on differences in epitope sequence. (A)
Plaque reduction and neutralization curves for five DENV-1 strains representing the five genotypes. The data is representative of three independent
experiments performed in duplicate. PRNT50 values are shown in Table 3. B–C. Serial six-fold dilutions of (B) DENV1-E103 or (C) E111 were
incubated with wild type or V345A West Pac-74 RVPs for one hour at 37uC, and then added to Raji-DC-SIGNR cells. Infection was assessed by flow
cytometry 48 hours later. One representative experiment of four is shown. The data is normalized relative to the infectivity of the RVPs in the absence
of antibody. Error bars indicate standard error of the mean of replicate infections.
doi:10.1371/journal.ppat.1002930.g003
Differential MAb Neutralization of DENV-1 Genotypes
PLOS Pathogens | www.plospathogens.org 8 October 2012 | Volume 8 | Issue 10 | e1002930
both 16007 and West Pac-74 after 22 hours at 37uC suggesting
that over time, a greater number of E111 epitopes become
exposed for binding (Figure 6A and B).
Because our SPR binding and structural data (Figures 1 and
2) did not correlate with neutralization experiments in which
amino acids of 16007 and West Pac-74 were exchanged
(Figure 3), we speculated that the interaction between E111
and amino acid 345 on DIII might be modulated by epitope
accessibility in a genotype-dependent manner. We evaluated the
effects on time and temperature on E111 neutralization of the
reciprocal pair of DENV-1 RVP, V345A West Pac-74 and A345V
16007. We observed enhanced E111 neutralization of V345A
West Pac-74 as a function of increased time and temperature
(Figure 6C and G); by 22 hours at 37uC or 7 hours at 40uC, the
EC50 value of V345A West Pac-74 RVP neutralization
approached that of the wild type 16007 RVP (Figure S4).
Neutralization of the A345V 16007 RVP by E111 also increased
with time and temperature (Figure 6D and H), although there
was no difference in EC50 value compared with wild type 16007
RVP. Overall, these experiments suggest that under steady-state
conditions, the ensemble of structures with respect to exposure of
the CC9 loop epitope are different between strains 16007 and West
Pac-74. Virion conformations sampled by individual DENV-1
genotypes likely vary with temperature and differ from those
described in existing cryo-electron microscopy models.
Discussion
Antibody neutralization of flaviviruses requires multiple anti-
bodies to bind a single virion until a neutralization threshold is
reached. The ability of a MAb to bind a given viral epitope
depends on its concentration, the affinity of its interaction with the
infectious virus particle, and the accessibility of the epitope on the
virion [11]. While some epitopes are readily accessible on the
surface of mature DENV, others are partially or completely
inaccessible [27,29,31,50]. However, antibodies that recognize
partially or completely occluded sites on the mature virion can still
neutralize flavivirus infection because of particle heterogeneity
with respect to maturation [29,50] and/or by sampling of
alternate ensemble structures or ‘‘breathing’’, which allows for
intermittent display of cryptic epitopes [31,32]. Here, our
structural studies show that E111 binds to a novel CC9 loop
epitope on DIII that does not appear to be affected by particle
maturation. Although the CC9 epitope is predicted to be
inaccessible on both the mature and immature virion, E111 still
potently neutralizes some but not all DENV-1 genotypes. While
the amino acid sequence of DIII varies among genotypes in and
around the CC9 loop, which affects E111 binding by SPR, there
was a limited relationship between the kinetics of binding in vitro
and the potency of genotypic neutralization in cell culture. Thus,
some aspect of E111 recognition and neutralization appears
independent of the epitope sequence. While E111-mediated
neutralization of strain 16007 was less affected by changes in
time or temperature of incubation, neutralization of West Pac-74
was enhanced substantially after incubation with E111 at higher
temperatures and for longer times. These experiments suggest that
at steady state, DENV-1 16007 has a broader ensemble of
conformations compared to West Pac-74, allowing for enhanced
exposure of particular DIII-specific epitopes for MAb neutraliza-
tion. This phenomenon could explain in part why so many (13 of
15) of our DIII-specific MAbs strongly neutralized infection of
strain 16007 but not West Pac-74 despite the relatively few amino
acid changes in DIII [17]. Several of our other anti-DENV-1
MAbs map to the lateral ridge epitope on DIII, which should be
fully exposed on the virion [51], and, in principle, not require
temperature or time-dependent changes in structure for enhanced
epitope accessibility. Nonetheless, in on-going studies, DIII lateral
ridge epitope-specific MAbs (e.g., DENV1-E102, DENV1-E103,
DENV1-E105, and DENV1-E106) all neutralized infection by
DENV-1 West Pac-74 more efficiently after an increase of
temperature and duration of incubation (K. Dowd and T. Pierson,
unpublished results). Thus, for DENV-1, structural perturbations
to the virion may influence neutralization by MAbs recognizing
ostensibly more and less exposed epitopes in a strain-dependent
manner.
Within DIII of different DENV-1 genotypes, the greatest
sequence variation occurs within and surrounding the CC9 loop (4
of 9 sites). In comparison, the CC9 loop residues of other DENV
serotypes are highly conserved: for DENV-2 and DENV-3
genotypes, only 2 of 8 and 1 of 11 sites, respectively, show amino
acid variation within or proximal to the CC9 loop. Neutralizing
antibodies that localize to the CC9 loop are not restricted to
DENV-1. We recently mapped four inhibitory DENV-2 MAbs to
residues within the CC9 loop by yeast surface display [18]. Several
of our DENV-2-specific CC9 loop MAbs protected against
DENV-2 challenge both as pre-exposure prophylaxis and post-
exposure therapy in mice. Due to the lack of a reproducible mouse
model for DENV-1 16007 infection, we have not assessed directly
the therapeutic efficacy of E111 under conditions where it is highly
neutralizing. Nonetheless, E111 was effective as prophylaxis
against DENV-1 West Pac-74 in an immunocompromised
AG129 mouse model of infection [17], despite its relatively poor
EC50 value in cell culture.
Flavivirus virions can undergo structural re-arrangements with
an increase of temperature, which can facilitate binding of
antibodies to epitopes with limited accessibility [31,32]. Indeed,
DENV-1 RVP showed markedly enhanced neutralization by E111
that was dependent on both time and temperature of incubation
with antibody. While these pre-incubation conditions alone
improved neutralization of West Pac-74 RVP by E111, insertion
of the V345A substitution (from 16007 into West Pac-74) was
required to shift the neutralization curve to achieve an EC50 value
of wild type 16007. This observation is consistent with a role for
amino acid 345 in E111 engagement and correlates with
differences in the binding of V345A and wild type DIII of West
Pac-74 observed by SPR. Thus, while a lack of E111 epitope
accessibility explains why West Pac-74 was not efficiently
neutralized under steady-state conditions, prolonged time and
higher temperature of incubation promoted sampling of a broader
ensemble of structures that revealed the differential effect of
Table 3. PRNT50 values of E111 against strains representing
five DENV-1 genotypes.
DENV-1 strain Genotype PRNT50 (ng/ml) ± SD
16007 2 3.8 (62.0)
3146 SL 5 21 (610)
Western Pacific-74 4 9,720 (63,180)
TVP-5175 3 .25,000 ng/ml
TVP-2130 1 .25,000 ng/ml
Neutralizing activity was determined by PRNT assay on Vero cells with
increasing concentrations of purified DENV1-E111 and 102 PFU of the indicated
DENV-1 genotypes. The data was derived from three independent experiments
performed in duplicate. PRNT50 values were calculated by non-linear regression
analysis and SD indicates the standard deviations.
doi:10.1371/journal.ppat.1002930.t003
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residue 345 on neutralization of West Pac-74. Interestingly, the
reciprocal mutation, A345V, when substituted into 16007 had
essentially no impact on neutralization by E111, regardless of the
time and temperature of incubation. While wild type DIII of
16007 binds E111 with a 37-fold longer half-life than the A345V
variant, the on-rates were equivalent. Thus, E111 binding and
neutralization may be preferentially determined by the on-rate
kinetics of antibody attachment through stabilization of a
potentially transient/infrequent conformation present in the
16007 ensemble of structures. Indeed, a mutant DIII of 16007
(K343I), which showed a substantially enhanced half-life of
binding interaction (,45 minutes) with E111, did not affect
neutralization potency (S. K. Austin, M. Diamond, and D.
Fremont, unpublished results).
Currently, there are no cryo-electron microscopy models of
DENV-1, whereas several models of DENV-2 have been
described [23,31,52]. These models were used as surrogates of
DENV-1 in an attempt to understand how E111 engaged its
epitope in the context of a virion. Due to the packing of individual
E protein monomers in the particle, there are limitations of
accessibility of antibodies to portions of the E protein depending
upon its particular symmetry environment. Examination of the
available cryo-electron microscopy models of DENV failed to
explain how E111 binds to the CC9 loop on the virion, as it is
completely inaccessible in all models, in all symmetry environ-
ments. DENV-2 particles are believed to sample ensemble of
conformations [32], as shown in the captured intermediate of the
cryo-electron microscopy reconstruction of DENV-2 with the
1A1D-2 Fab [31]. Despite a sizable increase in the relative E
protein surface area exposed in the 1A1D-2 captured intermedi-
ate, from a structural perspective there was still insufficient
accessibility to allow engagement by E111. Our crystallographic,
Figure 4. The structural basis of E111 neutralization. (A) E111 Fab docked onto the DENV-2 dimer (PDB 1OAN). Transparent gray space filled-
ribbon model of DENV-2 dimer with N-linked glycans colored green. The E111 Fab light (cyan) and heavy (magenta) chains are shown bound to the
equivalent DIII of the three dimensional structure within the DENV-2 dimer. The WNV E16 Fab (DIII lateral ridge antibody), in green and gold, (PDB
1ZTX) is docked onto the analogous DENV-2 residues for comparison. (B) Surface representation of the DENV-1 post-fusion trimer structure. Upper
panel: Each E protein in the trimer is colored independently (white, red and yellow), and the E111 epitope (colored as in Figure 1D) is mapped onto
DIII. The red surface of DI was made transparent to show the ribbon structure. Lower panel: The E111 scFv complex was superimposed onto a
monomer of the post-fusion trimer (white); The E111 scFv light chain (cyan) bound to DIII clashes with DI of the neighboring E monomer (red)
suggesting that E111 likely would inhibit formation of the E homotrimer required for virus fusion. Clashing beta strands from DI are labeled. (C) To
determine whether E111 neutralizes infection before or after cellular attachment, BHK21-15 cells were pre-chilled to 4uC, and 102 PFU of DENV-1
(16007) was added to each well for 1 h at 4uC. After extensive washing at 4uC, increasing concentrations of E111 were added for 1 h at 4uC, and the
PRNT protocol was then completed (dashed lines, Post). In comparison, a standard pre-incubation PRNT with all steps performed at 4uC is shown for
reference. In this case, virus and MAb were incubated together for 1 h at 4uC, prior to addition to cells (solid lines, Pre). Data shown are representative
from three experiments performed in duplicate.
doi:10.1371/journal.ppat.1002930.g004
Differential MAb Neutralization of DENV-1 Genotypes
PLOS Pathogens | www.plospathogens.org 10 October 2012 | Volume 8 | Issue 10 | e1002930
kinetic, and functional data all support a role for the CC9 loop in
E111 recognition yet the existing atomic models cannot explain
how it engages the virion. We speculate that a particular structural
ensemble allows exposure of the CC9 loop and binding of E111 for
certain DENV-1 genotypes. Indeed, we know little about the
alternate conformational states sampled by flaviviruses, as only two
cryo-electron microscopy models of transitional flavivirus states
exist: a low pH model of WNV E16 Fab and WNV, and the
1A1D-2 Fab binding to DENV-2 at physiological pH [31,53].
Further investigation using antibody captured virus conformations
are needed to explore the breadth of structures sampled by
flaviviruses.
Our structural and functional characterization of E111 has
implications for vaccine development and assessment. While
natural infection with DENV is believed to confer durable
protective immunity against homologous DENV serotypes, several
papers have reported disparate neutralization titers of homotypic
strains and genotypes after natural infection or immunization. The
neutralization potency of patient sera during the course of an
DENV-3 epidemic varied substantially for DENV-3 strains
corresponding to distinct genotypes [33]. A study of sera from
individuals experiencing DENV-1 infections also showed variable
neutralizing activity against different DENV-1 strains [35].
Moreover, pooled sera from monkeys immunized with a
tetravalent chimeric live attenuated DENV vaccine revealed a
range (e.g., ,12-fold for DENV-1 strains) of variability in EC50
neutralization titers against individual strains of a given DENV
serotype [38]. It remains possible that the differences are even
larger, as full neutralization profiles or EC90 values were not
reported in this latter study.
Studies examining how genotypic variation affects neutraliza-
tion with MAbs [16–18,54,55] suggest that natural sequence
variation among genotypes of a DENV serotype impacts the
potency of antibody neutralization. Analogously, many neutraliz-
ing antibodies against HIV, influenza, and hepatitis C viruses fail
to inhibit related stains and/or serotypes [56]. While the cryptic
nature of the CC9 loop may be a special case [17], we propose that
disparate neutralization of DENV-1 strains by monoclonal or
polyclonal antibodies could be due to or at least be affected by
differences in the ensemble of conformations sampled by the
virion. Selection of DENV strains that sample a greater diversity of
conformations as vaccine candidates could broaden the repertoire
of neutralizing antibodies against DENV. Such strains could better
expose and present the spectrum of epitopes available, and thereby
induce a more diverse neutralizing antibody repertoire. Alterna-
tively, the use of DENV strains or formulations with a limited
structural ensemble could focus the neutralizing antibody response
on specific epitopes whose accessibility is independent of time and
temperature, and thus, more effective at neutralizing a diverse
range of strains, regardless of particle conformation. Although a
monovalent formalin-fixed DENV-2 vaccine induced strongly
neutralizing antibodies against the parent strain in mice and
Figure 5. Mapping of the E111 epitope on the DENV virion. The
atomic structures of the (A) mature (PDB 1K4R), (B) immature (PDB
3C6D), and (C) 1A1D-2-bound DENV-2 (PDB 2R6P) are shown as
determined by modeling of cryo electron-microscopy reconstructions. E
proteins in each icosahedral symmetry axis are highlighted: yellow
(5-fold), blue (3-fold), or red (2-fold). The E111 epitope is colored in cyan
in each symmetry group. To visualize the localization of the E111
epitope (on the interior of the viral surface in certain axes) a cross-
section of each viral particle is shown. prM is colored in green on the
immature virus model. In panel C, the 1A1D-2 Fabs were removed
from the deposited cryo-electron microscopy structure to show only
the antibody-stabilized virus conformation.
doi:10.1371/journal.ppat.1002930.g005
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monkeys, it was never evaluated for activity against a range of
strains corresponding to different genotypes [57]. Clearly, further
empirical studies are necessary to assess directly how virion
ensembles affect immunogenicity as well as pathogenesis. Finally,
the conformational diversity of DENV strains used for diagnostic
evaluation of polyclonal serum could affect the interpretation of its
neutralizing potential; for example, the choice of a DENV strain
that cycles through limited structural conformations at 37uC for
neutralization assays could underestimate the quality of the
inhibitory activity of the antibody response in human serum.
In summary, we have defined a novel structural epitope on the
CC9 loop of DIII of DENV, which is not accessible in the existing
cryo-electron microscopy reconstruction models of DENV parti-
cles. Our experiments also suggest that the ensemble of
conformations of the DENV virion structure varies in a
genotype-dependent manner, which impacts the neutralizing
activity of antibodies and has direct implications for the
development and analysis of candidate DENV tetravalent
vaccines.
Materials and Methods
Protein production, purification, and crystallization
An untagged form of DENV-1 DIII (strain 16007, residues 293
to 399) was cloned into the pET21a vector (Novagen) and
expressed by autoinduction [58] in BL21 bacterial cells (Agilent).
Isolated inclusion bodies were solubilized and oxidatively re-
folded, as previously described [59]. Variants of the DENV-1
16007 strain (residues 293–399) were generated by site-directed
mutagenesis (QuikChange, Agilent) using unique primer sets
(Table S2). E111 scFv was engineered with a (GGGGS)3 linker
between the VL and VH and domains and a C-terminal
hexahistadine tag, cloned into the pAK400 vector, and expressed
in the periplasm of bacteria. The bacteria were lysed and the E111
scFv was purified by nickel affinity and size exclusion chromatog-
raphy. The scFv was complexed with excess DIII and purified by
size exclusion chromatography. The E111 scFv-DIII complexes
were crystallized at 10 mg/ml by sitting-drop vapor diffusion at
20uC using 20% polyethylene glycol (PEG) 3350, 0.2 M potassium
sulfate, and 5% glycerol. Crystals were cryo-protected in a solution
containing 35% glycerol and cooled in liquid nitrogen.
After protein A affinity purification, the E111 IgG was cleaved
with immobilized papain (Pierce Biotechnology), and Fabs were
recovered, as the Fc and uncleaved IgG were removed by passage
over a second protein A affinity column. West Pac-74 DIII and
E111 Fab were mixed and isolated by size exclusion chromatog-
raphy on a S75 Superdex column. The E111 Fab-DIII complexes
were crystallized at 15.8 mg/ml by sitting-drop vapor diffusion at
20uC using 0.1 M MES pH 5.3, 20% PEG 6000 (final pH 6.0)
with 1% glycerol. The crystals were cryo-protected in the mother
solution supplemented with 20% ethylene glycol and cooled in
liquid nitrogen.
Structure determination and refinement
Data were collected at APS beamline 19–ID (Argonne National
Laboratories) at 293u K and at a wavelength of 1.007 A˚ using a
CCD detector. Data were processed, scaled, and merged with
HKL-2000 [60]. Crystallographic phasing for the E111 scFv-DIII
complex was obtained by molecular replacement (PHENIX [61])
using the predicted scFv model given by the PIGS server [62] and
the atomic structure of DENV-1 16007 DIII (PBD accession
number 3IRC [17]). The crystals belong to the space group
P43212 with the unit cell dimensions of a = b = 135.224 and
c = 52.221, with one E111 scFv-DIII complex per asymmetric
unit. An atomic model was iteratively built in COOT [63] and
refined in PHENIX, and contained 328 amino acids (residues
298–396 from DIII, 1–114 of the E111 VH, and 1–107 of the
E111 VL, (Chothia numbering), 147 water molecules, four
chloride ions and one sulfate and glycol molecule each. The final
2.5 A˚ resolution model was refined to an Rwork = 19.6% and
Rfree = 23.9% for all F.0, with excellent geometry and Rama-
chandran angles (97.4% favored and 0.3% outliers).
Data for the E111 Fab-West Pac-74 DIII complex were initially
processed with centered orthorhombic symmetry with subsequent
identification of pseudo-merohedral twinning. The crystals actu-
ally belong to space group P21 and suffer ,30% twinning with the
operator h,-k,-h-l. The data was successfully phased by molecular
Figure 6. Neutralization of DENV-1 by E111 varies with time and temperature in a genotype-dependent manner. Serial dilutions of
E111 were incubated with (A and E) DENV-1 16007, (B and F) West Pac-74, (C and G) V345A West Pac-74, or (D and H) A345V 16007 RVP for 1 hour at
37uC before the addition of Raji-DC-SIGNR cells to establish reference neutralization curves. Additional DENV-1 RVP-E111 complexes were incubated
for 2, 4.5, 7, and 22 hours at 37uC (A–D) or 2 and 4.5 hours at 40uC (E–H) before addition to Raji-DC-SIGNR cells. Infection was carried out at 37uC and
determined by flow cytometry 48 hours later. One representative experiment of three is shown. The data is normalized relative to the infectivity of
the RVP in the absence of antibody at each time point for each temperature. Error bars indicate standard error of the mean of replicate infections.
doi:10.1371/journal.ppat.1002930.g006
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replacement using the E111 scFv-DIII complex and the constant
domains from PDB ID 4AEH with two molecules per asymmetric
unit. The atomic model was iteratively build in COOT and
refined in REFMAC [64] and PHENIX using jelly body and
reference model restrains, respectively. The structure contained
1060 amino acids (residues 299–395 from DIII, 1–212 from the
light chain, and 1–212 from the heavy chain (Chothia numbering).
The final 3.8 A˚ resolution model was refined to an Rwork = 23.7%
and Rfree = 27.8% for all F.0, with excellent geometry and
Ramachandran angles (97.0% favored and 0.4% outliers). The
atomic coordinates and structure factors have been deposited in
the Protein Data Bank (www.rcsb.org) under accession numbers
4FFY and 4FFZ for the scFv and Fab complexes, respectively.
Surface plasmon resonance
Kinetic information on the interaction between E111 and DIII
variants was obtained using a Biacore T100 instrument. Approx-
imately 500 response units (RU) of E111 or control MAb/scFv
(WNV E16) was immobilized using amine coupling to a Series S
CM5 chip. Once stabilized, a two-fold dilution series of the DENV
DIII variants were injected over the chip at a flow rate of 65 ml/
min for 180 seconds and allowed to dissociate for 1,000 seconds.
DIII had dissociated over this time period and additional
regeneration was not necessary. Data was processed using the
Biacore Evaluation Software (Version 1.1.1) by double referencing
and a 1:1 Langmuir fit of the curves. All curves were reference
subtracted from a flow cell containing the negative control WNV
E16 MAb/scFv. Maximum response units were plotted versus
concentration and this curve was fitted to determine the KD.
Results were generated from at least three independent experi-
ments, with a minimum of six binding curves per experiment.
Plaque reduction neutralization tests (PRNT)
PRNT were performed with the five DENV-1 genotype strains
with E111 on Vero cells as described previously [17]. In some
experiments, pre- or post-attachment studies were performed as a
variation [18,46]. Briefly, serially diluted MAbs were mixed 1:1
with 102 PFU of 16007 DENV-1 virus in DMEM containing 10%
FBS and incubated for one hour at 4uC. The virus-MAb mixture
was then added to the cells at 4uC, and after washing, incubated at
37uC for one additional hour. Alternatively, cells and media were
chilled to 4uC before 102 PFU of virus was added and incubated
for one hour. Unbound virus was washed away with chilled media
before the addition of E111 MAb. After one hour at 4uC, cells
were washed with warm media and overlaid with 2% low-melt
agarose (SeaPlaque) in modified Eagle medium and 4% FBS and
incubated at 37uC for 6 days. PRNT50 values were determined
using non-linear regression analysis (Graph Pad Prism4).
MAb neutralization of DENV-1 using RVP
DENV-1 RVP were generated as described previously [32,41].
Plasmids expressing the wild type or mutant capsid (C)-prM-E
genes of DENV-1 (strain 16007 or West Pac-74) were co-
transfected into HEK293T cells with a plasmid encoding a sub-
genomic WNV replicon expressing GFP. E protein variants were
engineered by site-directed mutagenesis (QuikChange, Agilent)
and confirmed by sequencing. Standard neutralization assays with
RVP were performed by incubating serial dilutions of antibody
with DENV-1 RVP for 1 hour at 37uC, followed by addition of
Raji-DC-SIGNR cells. Infection was carried out at 37uC and
monitored by flow cytometry 48 hours later for GFP expression.
To assess the role of temperature on MAb activity, neutralization
assays were performed as above, and designated as ‘‘reference’’
neutralization profiles. Additional RVP-antibody complexes,
following the initial 1 hour incubation at 37uC, were further
incubated at 37uC or 40uC for incremental lengths of time,
followed by infection of Raji-DC-SIGNR cells. Relative infectivity
was determined after comparison to infectivity of DENV-1 RVP
incubated at the same temperature in parallel in the absence of
antibody.
Effects of maturation on E111 MAb neutralization
RVP were produced from HEK293T cells to represent various
stages of maturation (standard (containing a heterogeneous
mixture of partially mature and mature) or mature (produced in
the presence of an over-expression of furin)) according to
published protocols [29]. Standard neutralization assays with
RVP were performed by incubating serial dilutions of antibody
with DENV-1 RVP for 1 hour at 37uC, followed by addition of
Raji-DC-SIGNR cells. Infection was carried out at 37uC and
monitored by flow cytometry 48 hours later for GFP expression.
To assess the role of temperature on MAb activity, neutralization
assays were performed as above, and designated as ‘‘reference’’
neutralization profiles.
Docking of E111 scFv onto structural models
(a) E protein dimer. Docking of the E111-DIII structure and the
WNV E16 Fab-DIII (PDB 1ZTX) onto the pre-fusion dimer
structure of DENV2 (PDB 1OAN) was based upon superimpo-
sition of DIII. (b) E protein trimer. The same procedure was used for
docking of the E111 scFv onto the post-fusion DENV-1 trimer
structure (PDB 3G7T). (c) Virions. The coordinates for the full
mature (PDB 1KR4), immature (PDB 3C6D), and 1A1D-2-bound
(PDB 2R6P) DENV-2 virus assemblies were downloaded from
VIPERdb [65] (http://viperdb.scripps.edu/). The surface of the
virus was clipped to reveal the interior of the virion models. All
structural representations were colored and rendered using
PyMOL (The PyMOL Molecular Graphics System, Version
1.4–1.5.1 Schro¨dinger, LLC., http://www.pymol.org).
Supporting Information
Figure S1 Expression and purification of proteins. (A) A
scheme of E111 scFv construct design, expression, and purification
with DIII of 16007. (B) A scheme of the proteolytic cleavage of the
E111 IgG2c molecule, purification, and complex purification with
DIII of West Pac-74. (C) Structural alignment of ribbon
representations of the two structures. The chain colors are as
follows: 16007 DIII (white), scFv light variable domain (cyan), scFv
heavy variable domain (magenta), and the E111 Fab-West Pac-74
structure is in light green. (D) Detailed hydrogen bonding
interactions of 16007 DIII CC9 loop residues (yellow) with E111
light (cyan) and heavy (magenta) chains, with interfacial waters
(red) evident on the composite electron density omit map.
(PDF)
Figure S2 The E111 epitope is occluded in the three
existing cryo-electron microscopic models of DENV for
different reasons. The equivalent residues were mapped onto
the surface of the DENV-2 mature cryo-electron microscopy
atomic reconstruction model (see Figure 5A; PDB 1K4R). The
orientation of bound E111 places the Fab within the plane of the E
protein arrangement on the viral surface (Figure S2A), DIII in
gold at the 3-fold axis. The contacts made by the E111 scFv
(Figure S2B, colored as in Figure 1D) are shown in contrast to
the contacts made by neighboring E proteins for the mature virus
in the two-fold (C), three-fold (D), or five-fold (E) axes of
symmetry. The DIII molecules are oriented and colored as in
Figure 1D, while the contacts of the adjacent E proteins are
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shown in red. The immature form of DENV-2 (PDB 3C6D) shows
a different impediment to E111 engagement. The formation of the
prM-E heterotrimers on the surface of the virus pushes the E111
epitope towards the interior of the virus (see Figure 5B).
Individual chains from the 2-fold (red), 3-fold (blue), and 5-fold
(yellow) associated with prM form the homotrimeric spikes on the
surface of the immature virus (Figure S2F–H). While the E
proteins from each chain contact at DIII (H), the repositioning of
DIII towards the interior of the immature virus (F, side view, and G,
bottom view) prevents its accessibility in this model. The model of
DENV complexed with the 1A1D-2 Fab (PDB 2R6P) is shown in
Figure 5C. The E111 epitope is surface accessible in all three
axes of symmetry, in contrast to that of the immature virus.
However, steric hindrance at the 3-fold (I) and 5-fold (J) axes due
to the tight spatial arrangement of neighboring DIII prohibits
E111 engagement. Adjacent E proteins do not contact DIII at the
2-fold axis. However, due to the orientation of the E111 epitope at
this axis, there is insufficient space for an intact IgG molecule to
bind (K, looking towards the center of the virus).
(PDF)
Figure S3 E111 neutralization occurs independently of
the maturation state of DENV-1 particles. A–D. Serial
dilutions of (A–B) E60 (DII-fusion loop) or (C–D) E111 (DIII CC9
loop) were added to the heterogeneous mixture of DENV-1 RVPs
released from cells using standard production conditions (std, green
triangles) or a more homogeneous mature population (mat, blue
circles) of (A and C) DENV-1 West Pac-74 or (B and D) DENV-1
16007 RVPs to determine the effect of the virus maturation state
on MAb neutralization. MAb-RVP complexes were incubated for
one hour at 37uC before being added to Raji-DC-SIGNR cells.
Infectivity was determined by flow cytometry 48 hours later. One
representative experiment of three is shown. The data is
normalized relative to the infectivity of the RVPs in the absence
of antibody. Error bars indicate standard error of the mean of
replicate infections.
(PDF)
Figure S4 Neutralization potency of DENV-1 by E111 for
V345A West Pac-74 RVPs approaches that of wild type
16007 RVPs with an increase of time and temperature.
Serial dilutions of E111 were incubated at (A) 37uC or (B) 40uC
with DENV-1 16007, West Pac-74, and V345A West Pac-74
RVPs for 1 hour or 22 hours before the addition of Raji-DC-
SIGNR cells to establish reference neutralization curves. Infection
was carried out at 37uC and determined by flow cytometry
48 hours later. One representative experiment of three is shown.
The data is normalized relative to the infectivity of the RVPs in
the absence of antibody at each time point for each temperature.
Error bars indicate standard error of the mean of replicate
infections.
(PDF)
Table S1 E111-DIII interface.
(PDF)
Table S2 DENV-1 DIII oligonucleotide primers.
(PDF)
Text S1 Supplemental methods and materials and
supplemental references.
(DOCX)
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